Blockchain Registration Transaction Record

Sigyn's CardioDialysis Unlocks Efficient Clinical Pathway, Targets $700M+ Market

Sigyn Therapeutics advances CardioDialysis for cardiovascular disease with new clinical pathway and corporate strategy targeting Nasdaq merger and reduced shareholder dilution.

This development represents a potential paradigm shift in cardiovascular disease treatment, particularly for high-risk dialysis patients who represent a vulnerable population with limited therapeutic options. Cardiovascular disease remains the leading global cause of mortality, and current treatments like statins only reduce adverse events by approximately 25%. CardioDialysis's approach—leveraging existing dialysis infrastructure at approximately 50,000 clinics worldwide—could democratize access to blood purification therapies that have shown 75-95% efficacy in clinical settings but have been restricted to specialized centers. For patients with end-stage renal disease, who face dramatically elevated cardiovascular risks and mortality rates, this technology could meaningfully extend life expectancy and quality of life. From an industry perspective, successful commercialization could disrupt the cardiovascular treatment landscape while creating substantial value for dialysis providers through new revenue streams. The company's strategic moves toward Nasdaq listing and private funding structures reflect broader trends in biotech financing, where innovative approaches to capital formation can determine which promising technologies reach patients.